DNA methyltransferase (DNMT) inhibitors such as 5-azacytidine (5-AZA) and 5-aza-2′deoxycytidine (decitabine) have been used for more than a decade in the treatment of AML patients with varying success rates and rapid development of treatment resistance [15]. Here, DNMT1 is linked to acute myeloid leukemia.